Torrent Pharmaceuticals Limited has launched Valzaar (Valsartan), an advanced angiotensin receptor blocker (ARB). This antihypertensive acts by specifically blocking AT1 receptor and thus inhibits Renin Angiotensin Aldosterone system. Valsartan is the most selective AT1 blocker amongst the available group of ARBs.

Valzaar is Torrent’s second product in the cardio vascular segment during the calendar year, after the successful national launch of Nebicard (Nebivolol).

The Rs 1800 crore cardio vascular market in India is growing at a rate of 13 per cent with the antihypertensive market growing at 14 per cent. Valzaar is expected to touch a sale of Rs 5 crore before the end of this fiscal.